Boston Scientific Corporation (BSX) : The total money flow in Boston Scientific Corporation (BSX) was negative ($8.92 million), which signals selling by the traders on Mondays session. They trimmed their holdings by selling the stock on downticks to the tune of $23.04 million. In comparison, the inflow of money into the stock on upticks was $14.12 million. The uptick to downtick ratio was 0.61. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $11.27 million. The value of transactions on uptick was $1.47 million. The negative money flow of ($9.8 million) confirms the selling in Boston Scientific Corporation (BSX) on strength. The uptick to downtick ratio of block trades was 0.13. Boston Scientific Corporation (BSX) gained $0.08 at $23.97, a gain of 0.33% over the previous days close. However, the stock registered -0.7% in the week.
Shares of Boston Scientific Corporation rose by 0.38% in the last five trading days and 1.65% for the last 4 weeks. Boston Scientific Corporation is up 5.73% in the last 3-month period. Year-to-Date the stock performance stands at 29.99%.
Boston Scientific Corporation (NYSE:BSX): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.98 and $23.83 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $24.08. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.97, notching a gain of 0.33% for the day. The total traded volume was 5,015,963 . The stock had closed at $23.89 on the previous day.
In a related news, Mahoney Michael F, director officer (President & CEO) of Boston Scientific Corp, unloaded 44,400 shares at an average price of $24.44 on August 1, 2016. The total amount of the transaction was worth $1,085,136, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.